Conference Coverage

Early liver transplant good for patients with severe alcoholic hepatitis


 

FROM THE LIVER MEETING 2017

Early liver transplantation was associated with good short-term survival in patients with severe alcoholic hepatitis, but a significant number of patients started consuming alcohol again, according to a study presented at the annual meeting of the American Association for the Study of Liver Diseases.

The study was a retrospective review of the ACCELERATE-AH trial, utilizing a cohort of 147 patients with severe AH who underwent liver transplant prior to a 6-month abstinence period and were discharged home after surgery, said Dr. Brian Lee of the University of California, San Francisco, and his colleagues. Patients also underwent a follow-up period with a median time of 1.6 years.

Pretransplant abstinence time was a median of 55 days, and 54% received steroids for alcoholic hepatitis before the surgery. A total of 141 patients were discharged home after surgery, and 132 survived past 3 months. Of the nine patients who died within 3 months of their liver transplant, eight had received steroid therapy, and five died from sepsis.

No deaths were reported between 3 months and 1 year post transplant, but nine deaths were reported after 1 year, seven of which were alcohol related. The probability of alcohol use after 1 year was 25% and was 34% after 3 years.

After adjustment, a lack of self-admission into a hospital was associated with alcohol usage post transplant, with a hazard ratio of 4.3. In multivariate analysis, any alcohol use post transplant was associated with death, with a hazard ratio of 3.9, Dr. Lee and his colleagues noted.

Dr. Lee, Dr. Mehta, Dr. Platt, Dr. Gurakar, Dr. Im, Dr. Han, Dr. Victor, Dr. Rinella, Dr. Maddur, Dr. Eswaran, Dr. Hause, Dr. Foley, Dr. Dodge, Dr. Li, and Dr. Terrault reported conflicts of interest.

Recommended Reading

Hepatitis C falls as barrier to heart transplantation
MDedge Family Medicine
Sharing drug paraphernalia alone didn’t transmit HCV
MDedge Family Medicine
VA shares its best practices to achieve HCV ‘cascade of cure’
MDedge Family Medicine
Fever, rash, and leukopenia in a 32-year-old man • Dx?
MDedge Family Medicine
Alcohol showed no cardiovascular benefits in nonalcoholic fatty liver disease
MDedge Family Medicine
Hepatitis C drug’s lower cost paves way for Medicaid, prisons to expand treatment
MDedge Family Medicine
To boost HCV testing in baby boomers, offer the option
MDedge Family Medicine
Study supports routine rapid HCV testing for at-risk youth
MDedge Family Medicine
New antiviral combination for HCV infection in kidney disease
MDedge Family Medicine
Targeted strategies better for birth cohort HCV testing
MDedge Family Medicine